468 results about "Phospholipase" patented technology

The present invention is directed to a process to remove impurities from triacylglycerol oil including mixing the oil and a fluidic agent, pumping the mixture through a flow-through hydrodynamic cavitation apparatus at a pre-determined inlet pump pressure, creating hydrodynamic cavitation in the mixture, maintaining the hydrodynamic cavitation for a pre-determined period of time, moving the impurities from the oil to the fluidic agent, and then separating the fluidic agent from the oil. The impurities can include phytosterols, sterol glucosides, acylated sterol glucosides, in which case the fluidic agent is water, an alkali hydroxide, an inorganic base, an organic base, phosphoric acid, citric acid, acetic acid or a mixture thereof. The impurities may also include phosphatides, in which case and the fluidic agent comprises water and an enzyme such as phospholipase, a lipid acyltransferase or a mixture thereof.

This disclosure describes genetically modified photosynthetic microorganisms, e.g., Cyanobacteria, that contain one or more exogenous genes encoding a phospholipase and / or thioesterase, which are capable of producing an increased amount of lipids and / or fatty acids. This disclosure also describes genetically modified photosynthetic microorganisms that contain one or more exogenous genes encoding a diacyglycerol acyltransferase, a phosphatidate phosphatase, and / or an acetyl-CoA carboxylase, which are capable of producing increased amounts of fatty acids and / or synthesizing triglycerides, as well as photosynthetic microorganism comprising mutations or deletions in a glycogen biosynthesis or storage pathway, which accumulate a reduced amount of glycogen under reduced nitrogen conditions as compared to a wild type photosynthetic microorganism.

In alternative embodiments, the invention provides phosphatidylinositol-specific phospholipase C (PI-PLC) enzymes, nucleic acids encoding them, antibodies that bind specifically to them, and methods for making and using them. Industrial methods and products comprising use of these phospholipases are also provided. In certain embodiments, provided herein are methods for hydration of non hydratable phospholipids (NHPs) within a lipid matrix. The methods enable migration of NHPs to an oil-water interface thereby allowing the NHPs to be reacted and / or removed from the lipids. In certain embodiments, provided is a method for removing NHPs, hydratable phospholipids, and lecithins from vegetable oils to produce a degummed oil or fat product that can be used for food production and / or non-food applications. In certain embodiments, provided herein are methods for hydration of NHPs followed by enzymatic treatment and removal of various phospholipids and lecithins. The methods provided herein can be practiced on either crude or water-degummed oils.

The invention provides novel polypeptides having phospholipase activity, including, e.g., phospholipase A, B, C and D activity, patatin activity, phosphatidic acid phosphatases (PAP) and / or lipid acyl hydrolase (LAH) activity, nucleic acids encoding them and antibodies that bind to them. Industrial methods, e.g., oil degumming, and products comprising use of these phospholipases are also provided.

This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA2α). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.

This invention relates to a method for refining crude soybean oil with immobilized phosphatidase. The method solves the problems of unable control of temperature and pH value, poor degumming effect of soybean oil, and high cost faced by the present enzyme degumming method. The method in this invention comprises: preparing the reactive solution, preparing a mixed solution, preparing granular immobilized phosphatidase, pre-treating crude soybean oil, adding immobilized phosphatidase into crude soybean oil, stirring and centrifuging. The method has such advantages as high degumming efficiency (increased by 0.5-2%) and low cost (decreased by 1-3%).

The invention discloses a Carassius aurutus gibelio compound feed and a preparation method thereof. The Carassius aurutus gibelio compound feed comprises the following components in percentage by weight: 3-5wt% of imported fish meal, 10-15wt% of domestic fish meal, 30-35wt% of bean pulp, 20-22wt% of rapeseed meal, 2-5wt% of cottonseed meal, 8-10wt% of rice bran, 3-5wt% of flour, 3-5wt% of oatmeal, 3-5wt% of soybean oil, 1-3wt% of monocalcium phosphate, 2wt% of premix, 1-2wt% of liquid phospholipid, 0.5wt% of enzymic preparation and 0.5wt% of Chinese herbal medicines. The compound feed provided by the invention has the advantages of balanced amino acid, proper energy-nitrogen ratio and calcium-phosphorus ratio, complete and abundant nutrition and reasonable proportion, and can be used for effectively improving the utilization ratio of feed, lowering bait coefficient, reducing nitrogen and phosphorus discharge, lightening water body pollution, and strengthening the immunity and the premonition of fish.

This invention relates to a method for measuring enzymatically active Lipoprotein Phospholipase A2 (Lp-PLA2) in a sample. Further, this invention relates to a Hybrid Immunocapture method for measuring enzymatically active Lp-PLA2 in a sample. Specifically, this invention relates to a Hybrid Immunocapture method for measuring enzymatically active Lp-PLA2 in a sample utilizing an enzymatically active Lp-PLA2 standard. In addition, this invention relates to a kit for measuring enzymatically active Lp-PLA2 in a sample. Specifically, this invention relates to a kit for measuring enzymatically active Lp-PLA2 in a sample containing an enzymatically active Lp-PLA2 standard.

The present invention provides for a method for identifying patients that are suitably treated by a therapy, such as a therapy involving administration of a fluoropyrimidine drug and / or a platinum drug. The method includes determining the expression level of at least one gene selected from a phospholipase 2 (PLA2) gene, a thymidine phosphorylase (TP) gene, and a glutathione S-transferase P1 (GSTP-1) gene in suitable sample isolated from the patient. Overexpression of the gene or genes identifies the patient as not being suitable for the therapy.

Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus or phospholipase A2 or to modulate the telomere length of a chromosome are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases and diseases associated with elevated levels of phospholipase A2 are also provided. Methods of modulating telomere length of a chromosome are also provided; modulation of telomere length is believed to play a role in the aging process of a cell and in control of malignant cell growth.

This invention provides methods for treating in mammals arthritic or rheumatic disorders using substituted indole compounds of the general formula:and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.

The invention relates to a novel chemical synthesis method of bromphenol PTP1B inhibitor which has a chemical structural formula as follows: wherein a group connected with 2,2' and the number 3, 3' carbon of benzene ring is bromine atom; 4,4' and the number 5, 5' carbon of the benzene ring are connected with hydroxy; and the PTP1B inhibitor has a chemical name in English: Bis-(2,3-dibromo-4,5-dimethoxy-phenyl)-methane. The compound negatively regulating an insulin signal transduction path by restricting the activity of protein tyrosine phospholipase 1B and has favorable curing effect for type 2 diabetes in insulin resistance types.

The invention discloses compositions for the preservation of fruits, vegetables, partially processed products, other produce and followers. The compositions comprise at least one phospholipase D inhibitor, at least one compound comprising an isoprene subunit, at least one component of the flavonoid biosynthetic pathway in a suitable medium. The composition of the present invention may additionally comprise one or more plant growth regulators of the cytokinin type, one or more antioxidants, a membrane stabilizing agent, a surfactant, or any combination thereof. The composition may be applied to produce as a spray, drench, dip, or a vapour and at either the pre-harvest stage or post-harvest stage.

The present invention relates to a method for identifying therapeutic agents for reducing and monitoring the growth, erosion, rupture or stability of an atherosclerotic plaque comprising the analysis of the differential expression of at least two genes coding proteins chosen among among Stearoyl CoA desaturase, Phosphatidic acid phosphate, and Phosphoinositide-specific-phospholipase-B1, eventually in association with the analysis of the differential expression of at least one gene coding a protein choosen in the group comprising Aldose reductase and aldehyde reductase, Sphingomyelinase, Acid ceramidase, Ceramide glucosyl transferase, Sphingosin phosphate liase, Thymosine beta 4, Aldehyde dehydogenase, ATPase Ca++ binding protein and CD163.

The present invention relates to a method for producing fatty acid alkyl esters, such as fatty acid methyl esters (FAME) and fatty acid ethyl esters with a low level of impurities such as phospholipids. The method of the invention is simplified by combining two process steps into one single process step and is therefore economically cheaper. The method includes mixing water, alcohol, triglyceride and / or free fatty acids a lipolytic enzyme and a phospholipase. Subsequently the aqueous phase, which contains glycerine, residual enzyme and most of the hydrolyzed phospholipids, is separated from the non-aqueous phase, whereby the content of phospholipids in the non-aqueous phase is reduced.

The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose of 2 μg to 60 μg, wherein said PTH peptide analogue has a reduced phospholipase-C activity and maintains adenylate cyclase activity.

The invention discloses a method for physically refining soybean crude oil and synchronously preparing soybean concentrated phospholipids employing enzymatic degumming. The method comprises the following steps: (1) taking soybean crude oil, and adding a citric acid to homogenize; (2) adding phospholipase and / or degummase to the homogenized soybean crude oil to homogenize; (3) stewing the crude oil homogenized in the step (2) for 1.5-3 hours, and then centrifugally separating, so as to obtain degummed oil and residues; (4) carrying out decolorizing, deodorizing and deacidifying on the degummed oil which is centrifugally separated in the step (3), so as to obtain product oil; (5) adding an organic solvent to remove neutral oil in the residues which are centrifugally separated in the step (3). By adopting enzymatic degumming, not only is a water resource saved, but also the produced product oil and residues are low in moisture, the quality of the phospholipids is easily controlled, and the product is stable in quality. Thus, the economic benefits are greatly improved.

The present invention provides methods of preventing and treating neural inflammatory or demyelinating disease, such as multiple sclerosis, via an inhibition of the activity or expression of phospholipase A2. The invention further relates to methods of identifying phospholipase A2 inhibitors and their use thereof for the prevention and / or treatment of neural inflammatory or demyelinating disease. An observed increase in the amount of phospholipase A2 in neural lesions in the EAE animal model system indicates that elevated phospholipase A2 activity or levels correlate with neural inflammatory or demyelinating disease. Therefore, in a further aspect the invention provides methods for the diagnosis and prognostication of neural inflammatory or demyelinating disease, such as multiple sclerosis.

An improved process for enzymatic reducing the content of phosphorus containing components in an edible oil. The method comprises the use of phospholipase and a low amount of water.

The invention provides a preparation method of instant yolk powder. The method comprises the following steps of: (a) carrying out mechanical dispersion on yolk liquid; (b) adding proteolytic enzyme, phospholipase and lipase to the yolk liquid, wherein the adding amount of the proteolytic enzyme meets the requirement that the weight ratio of the yolk liquid to the proteolytic enzyme is 100:(0.1-0.5), the adding amount of the lipase meets the requirement that the weight ratio of the yolk liquid to the lipase is 100:(0.01-0.05), and the adding amount of the phospholipase meets the requirement that the weight ratio of the yolk liquid to the phospholipase is 100:(0.01-0.05); and (c) carrying out drying treatment. According to the invention, through the synergistic action among the enzyme preparations, the solubility, emulsibility, heat resistance and the like of the yolk powder are improved.

The present invention provides novel polypeptides having phospholipase activity, including, for example, phospholipase A, B, C and D activities, potato tuber storage protein activity, fatty acyl hydrolase (LAH) activity, nucleic acids encoding them and antibodies that bind them . Industrial processes involving the use of these phospholipases, such as oil degumming, and products involving the use of these phospholipases are also provided.

A method for fractional measurement of small, dense LDL, which is adaptable for an autoanalyzer, and a reagent for measurement, are provided, making it possible to conduct rapid and convenient analysis with good sensitivity without pretreatment of a specimen. The method for quantitatively determining small, dense LDL cholesterol in a sample comprises the steps of:(1) eliminating cholesterol in LDL other than small, dense LDL in the presence of phospholipase; and(2) quantitatively determining cholesterol in lipoproteins remaining in step (1) above.

A new enzymatic process for preparing 1,2-diacylated phospholipids using an enzyme preparation possessing phospholipase activity towards acylation at the sn-1 and sn-2 sites in a microaqueous reaction system. More particularly, the 1,2-diacyl-phospholipids produced according to the esterification / transesterification process are obtainable in high yield and purity and carry identical desired carboxylic acid, preferably fatty acid, acyl groups at the sn-1 and sn-2 positions. The process involves esterification / transesterification (acylation) of a glycerophospholipid, preferably glycerophosphoryl choline (GPC) with a desired carboxylic acid, preferably fatty acid, or their derivatives in the presence of the above mentioned appropriate enzyme preparation. The process of the invention further relates to a process for the production of 1-acyl-2-lyso-glycerophospholipid, preferably 2-lyso-PC by reacting glycerophospholipid, preferably glycerophosphoryl choline (GPC) with a desired carboxylic acid, preferably fatty acid, or their derivatives in the presence of a sn-1 specific phospholipase (PLA1 or PLA1,2) and a solvent, in a microaqueous medium.

The invention discloses a method for preparing GPC by phospholipase-catalyzed hydrolysis and belongs to the technical field of lipid development and application. The method comprises the following steps: preparing GPC by using powdered phospholipid, alcohol soluble phospholipids, high-purity PC as raw materials and by phospholipase-catalyzed hydrolysis of phosphorylcholine (PC) in a water phase; and decolorizing by using active carbon to obtain GPC aqueous solution, converting into an alcohol phase, purifying by using a cation resin adsorption resolution and anion adsorption process to obtain high-purity GPC aqueous solution, performing rotating evaporation at a low temperature and under reduced pressure to obtain colorless transparent L-alpha-GPC solution, wherein the chemical purity of the obtained GPC is 98.8 percent, the optical purity ee of the obtained GPC is 99 percent, and the melting point (mp) of the obtained GPC is 142 to 143 DEG C (C is equal to 2.6, the H2O content is 14 percent and the pH value is 5.8). The invention provides a new thought and a new preparation method for preparing GPC and provides new application of phospholipase in lipid science.

The invention relates to a novel chemical synthesis method of brominated PTP1B inhibitor and the application thereof in the medicine for curing type 2 diabetes, wherein the brominated PTP1B inhibitor has a chemical structural formula as follows: wherein a group connected with 2,2' and the number 3, 3' carbon of benzene ring is bromine atom; 4,4' and the number 5, 5' carbon of the benzene ring are connected with methoxyl; and the PTP1B inhibitor has a chemical name in English: Bis-(2,3-dibromo-4,5-dimethoxy-phenyl)-methane. The compound can enhance the sensibility of insulin receptor by restricting the activity of protein tyrosine phospholipase 1B and has favorable curing effect for type 2 diabetes in insulin resistance types.

A modified phospholipase D having an ability to synthesize phosphatidylinositol which contains: (A) an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:2 by substitution of at least one of the amino acid residues at the 187-, 191- and 385-positions by other amino acid residue(s); or (B) an amino acid sequence of a polypeptide derived from the amino acid sequence as described in the above (A) by substitution, deletion, insertion and / or addition of at least one amino acid residue at a position different from the 187-, 191- and 385-positions and having an ability to synthesize phosphatidylinositol. By using this modified phospholipase D, phosphatidylinositol can be efficiently produced from a phospholipid. It is also intended to provide a method of screening a phospholipase D having an ability to synthesize an acylglycerophospholipid having glycol group.